In June 2008, misoprostol tablets were registered for prevention and treatment of postpartum hemorrhage (PPH) in Uganda. Following this significant policy step, in December 2008, the Ministry of Health approved the “Prevention and Treatment of Post Partum Haemorrhage Clinical Guidelines for the Use of Misoprostol,” which provide health care providers guidance on how to use the tablets to manage this important cause of maternal death and disability in Uganda.
VSI collaborated with the Ministry of Health which supportively took up the cause of reducing PPH-related maternal mortality by introducing the easy-to-use tablets in health centers. In this initial rollout of misoprostol for PPH which we launched with the Ministry and PACE in June 2009, we trained doctors, nurses and midwives to use misoprostol for PPH, and distributed the tablets in hospitals and health centers in 11 districts.
Misoprostol for Postpartum Hemorrhage Launch in Bugiri District, June 2009
By the Numbers
Estimated Total Population
Lifetime Risk of Maternal Death
1 woman in 35
Maternal Mortality Ratio
430 per 100,000 live-births
Total Fertility Rate
Births Attended by Skilled Health Provider
Unmet Need for Family Planning
Source: PRB, 2011 and WHO, 2010
Registered Misoprostol Product(s): Misotac®